|
Fiscal Period: December
|
2019 |
2020 |
2021 |
2022 |
2023 |
Capitalization1 |
9 914 | 19 891 | 47 536 | 25 459 | - |
Enterprise Value (EV)2 |
9 104 | 19 103 | 46 948 | 24 499 | 23 665 |
P/E ratio |
55,6x | 52,4x | 51,9x | 37,8x | 21,0x |
Yield |
2,02% | 1,12% | 0,56% | 1,17% | 1,42% |
Capitalization / Revenue |
16,5x | 28,1x | 29,3x | 16,1x | 10,1x |
EV / Revenue |
15,2x | 26,9x | 28,9x | 15,5x | 9,37x |
EV / EBITDA |
33,1x | 49,6x | 42,7x | 27,6x | 14,9x |
Price to Book |
9,16x | 15,8x | 16,2x | 7,01x | 4,46x |
Nbr of stocks (in thousands) |
952 984 | 952 984 | 986 646 | 995 309 | - |
Reference price (EUR) |
10,4 | 20,9 | 48,2 | 25,6 | 25,6 |
Announcement Date |
02/12/2020 | 01/26/2021 | 01/19/2022 | - | - |
1 SEK in Million 2 EUR in Million |
|
|
Income Statement Evolution (Annual data) |
|
Fiscal Period: December
|
2019 |
2020 |
2021 |
2022 |
2023 |
Net sales1 |
600 | 709 | 1 623 | 1 582 | 2 526 |
EBITDA1 |
275 | 385 | 1 100 | 887 | 1 592 |
Operating profit (EBIT)1 |
245 | 350 | 1 063 | 825 | 1 533 |
Operating Margin |
40,8% | 49,4% | 65,5% | 52,1% | 60,7% |
Pre-Tax Profit (EBT)1 |
173 | 311 | 878 | 750 | 1 485 |
Net income1 |
160 | 379 | 909 | 684 | 1 360 |
Net margin |
26,7% | 53,5% | 56,0% | 43,2% | 53,8% |
EPS2 |
0,19 | 0,40 | 0,93 | 0,68 | 1,22 |
Dividend per Share2 |
0,21 | 0,23 | 0,27 | 0,30 | 0,36 |
Announcement Date |
02/12/2020 | 01/26/2021 | 01/19/2022 | - | - |
1 EUR in Million 2 EUR |
|
|
Income Statement Evolution (Quarterly data) |
|
Fiscal Period: December
|
2019 S2 |
2020 S1 |
2020 S2 |
2021 S1 |
2021 S2 |
2022 S1 |
2022 S2 |
Net sales1 |
304 | 264 | 444 | 709 | 912 | 733 | 851 |
EBITDA1 |
- | 80,0 | 305 | 492 | 608 | 413 | 427 |
Operating profit (EBIT)1 |
- | 63,0 | 286 | 476 | 587 | 393 | 447 |
Operating Margin |
- | 23,9% | 64,4% | 67,1% | 64,4% | 53,6% | 52,6% |
Pre-Tax Profit (EBT) |
- | 68,0 | 243 | 397 | 481 | - | - |
Net income |
- | - | 332 | 361 | 548 | - | - |
Net margin |
- | - | 74,8% | 50,9% | 60,1% | - | - |
EPS |
- | 0,06 | 0,35 | 0,37 | - | - | - |
Dividend per Share |
- | - | - | - | - | - | - |
Announcement Date |
02/12/2020 | 08/20/2020 | 01/26/2021 | 07/22/2021 | 01/19/2022 | 07/14/2022 | - |
1 EUR in Million |
|
|
|
Fiscal Period: December
|
2019 |
2020 |
2021 |
2022 |
2023 |
Net Debt1 |
- | - | - | - | - |
Net Cash position1 |
810 | 789 | 588 | 961 | 1 795 |
Leverage (Debt / EBITDA) |
-2,95x | -2,05x | -0,53x | -1,08x | -1,13x |
Free Cash Flow1 |
226 | 163 | 597 | 609 | 1 337 |
ROE (Net Profit / Equities) |
22,6% | 32,3% | 43,2% | 17,6% | 24,5% |
Shareholders' equity1 |
706 | 1 172 | 2 103 | 3 893 | 5 560 |
ROA (Net Profit / Asset) |
16,4% | 24,8% | 33,0% | 16,8% | 22,8% |
Assets1 |
977 | 1 526 | 2 758 | 4 080 | 5 972 |
Book Value Per Share2 |
1,14 | 1,32 | 2,98 | 3,65 | 5,73 |
Cash Flow per Share2 |
0,29 | 0,18 | 0,62 | 0,77 | 1,30 |
Capex1 |
18,0 | 8,40 | 11,0 | 18,1 | 21,1 |
Capex / Sales |
3,00% | 1,18% | 0,68% | 1,15% | 0,84% |
Announcement Date |
02/12/2020 | 01/26/2021 | 01/19/2022 | - | - |
1 EUR in Million 2 EUR |
|
| |
|
|
EQT's Galderma announces positive trial results on skin drug |
Capitalization (SEK) |
266 444 228 937 |
Capitalization (USD) |
26 104 247 696 |
Net sales (EUR) |
709 000 000 |
Net sales (USD) |
726 955 808 |
Number of employees |
1 356 |
Sales / Employee (EUR) |
522 861 |
Sales / Employee (USD) |
536 103 |
Free-Float |
37,3% |
Free-Float capitalization (SEK) |
99 408 221 123 |
Free-Float capitalization (USD) |
9 739 287 045 |
Avg. Exchange 20 sessions (EUR) |
246 892 362 |
Avg. Exchange 20 sessions (USD) |
253 145 044 |
Average Daily Capital Traded |
0,09% |
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
|